• Patient Stories
  • Understanding MPNs
    • Understanding MPNS
    • What Is Polycythemia Vera?
    • What Is Essential Thrombocythemia?
    • What Is Primary Myelofibrosis?
  • Resources
    • Empowered Patients
    • Dictionary
    • Resources
  • Partners
    • Industry Partners
    • International MPN Organizations
    • Partners
  • News Feed
  • Contact
  • MPN Search

PV Reporter

MPN Information and Research Hub

  • About
    • About Us
    • MPN Cancer Connection
    • Contact Us
  • MPN Specialists
  • Blog
  • Media
    • Podcast
      • 01: Polycythemia Vera Diagnosis, PV Reporter, Day 1, Doomsday or Living with a Plan
      • 02: MPN Chronicles – Interview with Dr. Pemmaraju
      • 03: Learn Benefits of Becoming your own MPN Advocate
      • 04: First Hematologist appointment for PV patient
      • 05: Tips to Living Well with an MPN
      • 06: My Plan to beat Coronavirus Blues
    • Videos
    • Dr. Interviews
      • Dr. Jean Jacques Kiladjian ASH 2018 RuxoPeg Phase 1/2 Trial of the Combo of Ruxolitinib and Pegasys in Myelofibrosis Patients
      • Dr. Michael Grunwald ASH 2018 Risk Assessment and Treatment Myelofibrosis Patients at Community Oncology Practices in the U.S.
      • Dr. J.J. Kiladjian ASH 2018 Headline Research Studies
      • ASH 2017 Interview with Dr. Michael Grunwald
        • ASH 2017 Interview with Dr. Raajit Rampal, part 1
        • ASH 2017 with Dr. Raajit Rampal, part 2
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 1
        • ASH 2017 Interview with Dr. Jean Jacques Kiladjian, part 2
      • ASH 2016 Interviews
        • ASH 2016 Interview with Dr Kiladjian
        • ASH 2016 Interview with Dr Rampal
      • ASH 2015 Interviews
        • ASH 2015 Interview with Dr John Mascarenhas
        • ASH 2015 Interview with Dr Angela Fleischman
      • ASH 2014 Interviews
        • ASH 2014 Interview with Dr Heinz Gisslinger
        • ASH 2014 interview with Dr Richard Stone
  • Treatment
    • How I Treat MPN’s
    • Jakafi
    • INREBIC
    • Interferon treatment for MPNs
  • Support Group

Clinical Trial Finder

Search Results

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Study Purpose

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Subjects must satisfy the following criteria to be randomized in the study: 1. Subject is ≥18 years of age at the time of signing the ICF. 2. Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO) criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria , confirmed by the most recent local pathology report. 3. Subject is requiring RBC transfusions as defined as: a. Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to randomization. There must be no interval > 6 weeks (42 days) without ≥ 1 RBC transfusion. b. RBC transfusions are scored in determining eligibility when given for treatment of:
  • - Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤ 9.5 g/dL or.
  • - Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL c.
RBC transfusions given for worsening of anemia due to bleeding or infections are not scored in determining eligibility. 4. Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive weeks) JAK2 inhibitor therapy as approved in the country of the study site for the treatment for MPN-associated MF as part of their standard-of-care therapy for at least 32 weeks, on stable daily dose for at least 16 weeks immediately up to the date of randomization and anticipated to be on a stable daily dose of that JAK2 inhibitor for at least 24 weeks after randomization. 5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2. 6. A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP)participating in the study must: a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the subject practices true abstinence* from heterosexual contact. b. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception** without interruption, 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy. 7. Male subjects must: Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy. * True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.] ** Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception: Oral, Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence. 8. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 9. Subject is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.

Exclusion Criteria:

The presence of any of the following will exclude a subject from randomization: 1. Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration). 2. Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids or other drugs with potential effects on hematopoiesis ≤ 8 weeks immediately up to the date of randomization. 1. Systemic corticosteroids are permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to randomization. 2. Iron chelation therapy (ICT) is permitted providing the subject is receiving a stable dose for the 8 weeks immediately up to randomization. 3. Subject with any of the following laboratory abnormalities at screening: 1. Neutrophils: < 1 x 109/L. 2. White blood count (WBC): > 100 x 109/L. 3. Platelets: the lowest allowable level as approved for the concomitant JAK2 inhibitor but not < 25 x 109/L or > 1000 x 109/L. 4. Peripheral blood myeloblasts:> 5% 5. Estimated glomerular filtration rate:< 40 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [MDRD] formula) or nephrotic subjects (eg, urine albumin-to-creatinine ratio > 3500 mg/g) 6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):> 3.0 x upper limit of normal (ULN) 7. Direct bilirubin: ≥ 2 x ULN.
  • - Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis) 4.
Subject with uncontrolled hypertension, defined as repeated elevations of systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved at the time of randomization. 5. Subject with prior history of malignancies, other than disease under study, unless the subject has been free of the disease for ≥ 3 years. However, subject with the following history/concurrent conditions is allowed: 1. Basal or squamous cell carcinoma of the skin. 2. Carcinoma in situ of the cervix. 3. Carcinoma in situ of the breast. 4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) 6. Subject with prior hematopoietic cell transplant or subject anticipated to receive a hematopoietic cell transplant during the 24 weeks from the date of randomization. 7. Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the date of randomization. 8. Subject with major surgery within 2 months up to the date of randomization. Subject must have completely recovered from any previous surgery immediately up to the date of randomization. 9. Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization. 10.Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction < 35%. 11.Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment). 12.Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B (HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C (HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient sensitivity. 13.Subject with prior therapy of luspatercept or sotatercept. 14.Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product. 15.Pregnant or breastfeeding females. 16.Subject participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, immediately up to the date of randomization. 17.Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study or places the subject at unacceptable risk if he/she were to participate in the study. 18.Subject with any condition or concomitant medication that confounds the ability to interpret data from the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04717414
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Celgene
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Additional Details

Permitted Concomitant Medications and Procedures.

  • - Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted.
JAK2 inhibitors are to be used according to their respective label and as prescribed as part of the subject's standard-of-care therapy as prescribed by their physician prior to study entry.
  • - Best supportive care (BSC) includes, but is not limited to, treatment with transfusions (eg, RBC, platelet, whole blood), ICTs, antibiotic, antiviral and/or antifungal therapy, and nutritional support as needed.
  • - Granulocyte colony-stimulating factors (ie, G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF]) are allowed only in cases of neutropenic fever or as clinically indicated per product label.
  • - Prophylactic antithrombotic therapy is permitted.
  • - Thrombopoietin and platelet transfusions are permitted.
  • - Treatment with systemic corticosteroids is permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone during the study.
  • - Administration of attenuated vaccines (eg, influenza vaccine) is allowed if clinically indicated per Investigator discretion.
  • - Iron chelation therapy (ICT) is to be used according to the product label.
If the label permits, the ICT dose should be stable during at least the first 24 weeks of IP. Initiation of ICT while within the first 24 weeks of IP should be clinically indicated to treat an AE. Prohibited Concomitant Medications. The following concomitant medications are specifically excluded during the course of the study:
  • - Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapies (excluding JAK2 inhibitor therapy) - Azacitidine, decitabine, or other hypomethylating agents.
  • - Lenalidomide, thalidomide, and pomalidomide.
  • - Erythropoietin stimulating agents (ESAs) and other RBC hematopoietic growth factors (eg, IL-3) - Hydroxyurea or other alkylating agents.
  • - Androgens (unless given to treat hypogonadism) - Oral retinoids (topical retinoids are permitted) - Arsenic trioxide.
  • - Interferon.
  • - Anagrelide.
  • - Systemic corticosteroids at a dose equivalent to > 10 mg prednisone.
- Investigational products for the treatment of MPN-associated MF

Arms & Interventions

Arms

Experimental: Experimental Arm: Luspatercept (ACE-536)

Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)

Placebo Comparator: Control Arm: Placebo

Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)

Interventions

Drug: - ACE-536

Subcutaneous Injection

Other: - Placebo

Subcutaneous Injection

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of California San Diego, La Jolla, California

Status

Not yet recruiting

Address

University of California San Diego

La Jolla, California, 92037

Site Contact

Clinical.Trials@bms.com

855-907-3286

University of California Los Angeles, Los Angeles, California

Status

Not yet recruiting

Address

University of California Los Angeles

Los Angeles, California, 90095

Site Contact

Clinical.Trials@bms.com

855-907-3286

Northwestern University, Chicago, Illinois

Status

Not yet recruiting

Address

Northwestern University

Chicago, Illinois, 60611

Site Contact

Clinical.Trials@bms.com

855-907-3286

Rush University Medical Center, Chicago, Illinois

Status

Recruiting

Address

Rush University Medical Center

Chicago, Illinois, 60612

Site Contact

Clinical.Trials@bms.com

855-907-3286

Ann Arbor, Michigan

Status

Recruiting

Address

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

Site Contact

Clinical.Trials@bms.com

855-907-3286

Washington University, Saint Louis, Missouri

Status

Recruiting

Address

Washington University

Saint Louis, Missouri, 63110

Site Contact

Clinical.Trials@bms.com

855-907-3286

John Theurer Cancer Center, Hackensack, New Jersey

Status

Not yet recruiting

Address

John Theurer Cancer Center

Hackensack, New Jersey, 07601

Site Contact

Clinical.Trials@bms.com

855-907-3286

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Not yet recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10021-6094

Site Contact

Clinical.Trials@bms.com

855-907-3286

Mount Sinai Medical Center, New York, New York

Status

Recruiting

Address

Mount Sinai Medical Center

New York, New York, 10029

Site Contact

Clinical.Trials@bms.com

855-907-3286

Cleveland Clinic Foundation, Cleveland, Ohio

Status

Not yet recruiting

Address

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Site Contact

Clinical.Trials@bms.com

855-907-3286

Pittsburgh, Pennsylvania

Status

Not yet recruiting

Address

West Penn Allegheny Lupus Center of Excellence

Pittsburgh, Pennsylvania, 15224

Site Contact

Clinical.Trials@bms.com

855-907-3286

Houston, Texas

Status

Recruiting

Address

The University of Texas - MD Anderson Cancer Center

Houston, Texas, 77030

Site Contact

Clinical.Trials@bms.com

855-907-3286

San Antonio, Texas

Status

Not yet recruiting

Address

CTRC at The UT Health Science Center at San Antonio

San Antonio, Texas, 78229

Site Contact

Clinical.Trials@bms.com

855-907-3286

Salt Lake City, Utah

Status

Not yet recruiting

Address

University of Utah - Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Site Contact

Clinical.Trials@bms.com

855-907-3286

International Sites

Monash Medical Centre, Clayton, Victoria, Australia

Status

Recruiting

Address

Monash Medical Centre

Clayton, Victoria, 3168

Site Contact

Clinical.Trials@bms.com

855-907-3286

The Alfred Hospital, Melbourne, Victoria, Australia

Status

Recruiting

Address

The Alfred Hospital

Melbourne, Victoria, 3004

Site Contact

Clinical.Trials@bms.com

855-907-3286

Gosford Hospital, Gosford, Australia

Status

Recruiting

Address

Gosford Hospital

Gosford, , 2250

Site Contact

Clinical.Trials@bms.com

855-907-3286

Royal Hobart Hospital, Hobart, Australia

Status

Recruiting

Address

Royal Hobart Hospital

Hobart, , 7000

Site Contact

Clinical.Trials@bms.com

855-907-3286

Medizinische Universitat Graz, Graz, Austria

Status

Recruiting

Address

Medizinische Universitat Graz

Graz, , 8036

Site Contact

Clinical.Trials@bms.com

855-907-3286

Linz, Austria

Status

Recruiting

Address

Krankenhaus der Elisabethinen Linz, I Interne Abteilung

Linz, , 4020

Site Contact

Clinical.Trials@bms.com

855-907-3286

Vienna, Austria

Status

Recruiting

Address

Medizinische Universitat Wien, Universitatsklinik fur Dermatologie. Abteilung fur Immundermatologie

Vienna, , 1090

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hanusch Krankenhaus, Wien, Austria

Status

Recruiting

Address

Hanusch Krankenhaus

Wien, , 1140

Site Contact

Clinical.Trials@bms.com

855-907-3286

AZ Sint-Jan AV Brugge, Brugge, Belgium

Status

Recruiting

Address

AZ Sint-Jan AV Brugge

Brugge, , 8000

Site Contact

Clinical.Trials@bms.com

855-907-3286

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Status

Recruiting

Address

Cliniques Universitaires Saint-Luc

Brussels, , 1200

Site Contact

Clinical.Trials@bms.com

855-907-3286

Virga Jessa Ziekenhuis, Hasselt, Belgium

Status

Recruiting

Address

Virga Jessa Ziekenhuis

Hasselt, , 3500

Site Contact

Clinical.Trials@bms.com

855-907-3286

UZ Leuven, Leuven, Belgium

Status

Recruiting

Address

UZ Leuven

Leuven, , 3000

Site Contact

Clinical.Trials@bms.com

855-907-3286

AZ Delta, Roeselare, Belgium

Status

Recruiting

Address

AZ Delta

Roeselare, , 8800

Site Contact

Clinical.Trials@bms.com

855-907-3286

Centre Hospitalier Peltzer - La Tourelle, Verviers, Belgium

Status

Recruiting

Address

Centre Hospitalier Peltzer - La Tourelle

Verviers, , 4800

Site Contact

Clinical.Trials@bms.com

855-907-3286

Yvoir, Belgium

Status

Recruiting

Address

Cliniques Universitaires UCL de Mont-Godine

Yvoir, , 5530

Site Contact

Clinical.Trials@bms.com

855-907-3286

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Status

Recruiting

Address

Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2

Site Contact

Clinical.Trials@bms.com

855-907-3286

University of Alberta Hospital, Edmonton, Alberta, Canada

Status

Recruiting

Address

University of Alberta Hospital

Edmonton, Alberta, T6G 2S2

Site Contact

Clinical.Trials@bms.com

855-907-3286

St. Paul's Hospital, Vancouver, British Columbia, Canada

Status

Recruiting

Address

St. Paul's Hospital

Vancouver, British Columbia, V6Z 2A5

Site Contact

Clinical.Trials@bms.com

855-907-3286

Saint John Regional Hospital, Saint John, New Brunswick, Canada

Status

Not yet recruiting

Address

Saint John Regional Hospital

Saint John, New Brunswick, E2L 4L2

Site Contact

Clinical.Trials@bms.com

855-907-3286

London Health Sciences Centre, London, Ontario, Canada

Status

Recruiting

Address

London Health Sciences Centre

London, Ontario, N6C 6B5

Site Contact

Clinical.Trials@bms.com

855-907-3286

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Status

Recruiting

Address

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Status

Recruiting

Address

Hopital Maisonneuve-Rosemont

Montreal, Quebec, H1T 2M4

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 182, Montreal, Quebec, Canada

Status

Recruiting

Address

Local Institution - 182

Montreal, Quebec, H3T 1E2

Site Contact

Site 182

Clinical.Trials@bms.com

855-907-3286

Sir Mortimer B. Davis - Jewish Genl, Montreal, Quebec, Canada

Status

Recruiting

Address

Sir Mortimer B. Davis - Jewish Genl

Montreal, Quebec, H3T 1E2

Site Contact

Clinical.Trials@bms.com

855-907-3286

Sherbrooke, Quebec, Canada

Status

Recruiting

Address

Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont

Sherbrooke, Quebec, J1H5N4

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 807, Guangzhou, Guangdong, China

Status

Recruiting

Address

Local Institution - 807

Guangzhou, Guangdong, 510515

Site Contact

Site 807

Clinical.Trials@bms.com

855-907-3286

Peking Union Medical College Hospital, Beijing, China

Status

Not yet recruiting

Address

Peking Union Medical College Hospital

Beijing, , 100730

Site Contact

Clinical.Trials@bms.com

855-907-3286

First Hospital of Jilin University, Changchun, China

Status

Not yet recruiting

Address

First Hospital of Jilin University

Changchun, , 130021

Site Contact

Clinical.Trials@bms.com

855-907-3286

Guangdong General Hospital, Guangzhou, China

Status

Not yet recruiting

Address

Guangdong General Hospital

Guangzhou, , 510030

Site Contact

Clinical.Trials@bms.com

855-907-3286

Guangzhou, China

Status

Recruiting

Address

Nanfang Hospital of Southern Medical University

Guangzhou, , 510515

Site Contact

Clinical.Trials@bms.com

855-907-3286

Harbin, China

Status

Recruiting

Address

The First Affiliated Hospital of Harbin Medical University

Harbin, , 150081

Site Contact

Clinical.Trials@bms.com

855-907-3286

Nanjing, China

Status

Not yet recruiting

Address

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University

Nanjing, , 210029

Site Contact

Clinical.Trials@bms.com

855-907-3286

Shanghai, China

Status

Not yet recruiting

Address

Ruijin Hospital Shanghai Jiaotong University

Shanghai, , 200025

Site Contact

Clinical.Trials@bms.com

855-907-3286

Shanghai 6th Hospital, Shanghai, China

Status

Not yet recruiting

Address

Shanghai 6th Hospital

Shanghai, , 200233

Site Contact

Clinical.Trials@bms.com

855-907-3286

Suzhou, China

Status

Not yet recruiting

Address

The First Affiliated Hospital of Soochow University

Suzhou, , 215006

Site Contact

Clinical.Trials@bms.com

855-907-3286

Tianjin, China

Status

Recruiting

Address

Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, , 300041

Site Contact

Clinical.Trials@bms.com

855-907-3286

Henan Cancer Hospital, Zhengzhou, China

Status

Not yet recruiting

Address

Henan Cancer Hospital

Zhengzhou, ,

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 341, Prague 2, Czechia

Status

Recruiting

Address

Local Institution - 341

Prague 2, , 128 08

Site Contact

Site 341

Clinical.Trials@bms.com

855-907-3286

Vseobecna Fakultni Nemocnice v Praze, Prague 2, Czechia

Status

Recruiting

Address

Vseobecna Fakultni Nemocnice v Praze

Prague 2, , 128 08

Site Contact

Clinical.Trials@bms.com

855-907-3286

CHRU Hopital du Bocage, Angers, France

Status

Recruiting

Address

CHRU Hopital du Bocage

Angers, , 49033

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hopital Henri Mondor, Creteil, France

Status

Recruiting

Address

Hopital Henri Mondor

Creteil, , 94010

Site Contact

Clinical.Trials@bms.com

855-907-3286

CHU de Grenoble, Grenoble, France

Status

Recruiting

Address

CHU de Grenoble

Grenoble, , 38043

Site Contact

Clinical.Trials@bms.com

855-907-3286

CHRU de Lille-Hopital Claude Huriez, Lille, France

Status

Recruiting

Address

CHRU de Lille-Hopital Claude Huriez

Lille, , 59037

Site Contact

Clinical.Trials@bms.com

855-907-3286

Centre Leon Berard, Lyon, France

Status

Recruiting

Address

Centre Leon Berard

Lyon, , 69008

Site Contact

Clinical.Trials@bms.com

855-907-3286

CHU de Nice Archet I, Nice, France

Status

Recruiting

Address

CHU de Nice Archet I

Nice, , 06202

Site Contact

Clinical.Trials@bms.com

855-907-3286

Nimes Cedex 9, France

Status

Recruiting

Address

Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau

Nimes Cedex 9, , 30029

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hopital Saint Louis, Paris Cedex 10, France

Status

Recruiting

Address

Hopital Saint Louis

Paris Cedex 10, , 75475

Site Contact

Clinical.Trials@bms.com

855-907-3286

Pessac, France

Status

Recruiting

Address

Groupe Hospitalier Sud Hopital Haut Leveque USN

Pessac, , 33604

Site Contact

Clinical.Trials@bms.com

855-907-3286

CHU La Miletrie, Poitiers Cedex, France

Status

Recruiting

Address

CHU La Miletrie

Poitiers Cedex, , 86021

Site Contact

Clinical.Trials@bms.com

855-907-3286

Strasbourg, France

Status

Recruiting

Address

ICANS Institut de cancerologie Strasbourg Europe

Strasbourg, , 67200

Site Contact

Clinical.Trials@bms.com

855-907-3286

Toulouse Cedex 9, France

Status

Recruiting

Address

Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse Cedex 9, , 31059

Site Contact

Clinical.Trials@bms.com

855-907-3286

Unviversitatsklinikum Aachen, Aachen, Germany

Status

Recruiting

Address

Unviversitatsklinikum Aachen

Aachen, , 52074

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 294, Baden-Warttemberg, Germany

Status

Recruiting

Address

Local Institution - 294

Baden-Warttemberg, , 73557

Site Contact

Site 294

Clinical.Trials@bms.com

855-907-3286

Stauferklinikum Schwab. Gmund, Baden-Warttemberg, Germany

Status

Recruiting

Address

Stauferklinikum Schwab. Gmund

Baden-Warttemberg, , 73557

Site Contact

Clinical.Trials@bms.com

855-907-3286

Universitaetsklinikum Duesseldorf, Dusseldorf, Germany

Status

Recruiting

Address

Universitaetsklinikum Duesseldorf

Dusseldorf, , 40225

Site Contact

Clinical.Trials@bms.com

855-907-3286

Universitatsklinikum Halle Saale, Halle, Germany

Status

Recruiting

Address

Universitatsklinikum Halle Saale

Halle, , 06120

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 300, Hamburg, Germany

Status

Recruiting

Address

Local Institution - 300

Hamburg, , 22081

Site Contact

Site 300

Clinical.Trials@bms.com

855-907-3286

OncoResearch Lerchenfeld GmbH, Hamburg, Germany

Status

Recruiting

Address

OncoResearch Lerchenfeld GmbH

Hamburg, , 22081

Site Contact

Clinical.Trials@bms.com

855-907-3286

Universitaetsklinikum Jena, Jena, Germany

Status

Recruiting

Address

Universitaetsklinikum Jena

Jena, , 07740

Site Contact

Clinical.Trials@bms.com

855-907-3286

Universitatsklinikum Leipzig, Leipzig, Germany

Status

Recruiting

Address

Universitatsklinikum Leipzig

Leipzig, , 04103

Site Contact

Clinical.Trials@bms.com

855-907-3286

Universitaetsklinikum Mannheim, Mannheim, Germany

Status

Recruiting

Address

Universitaetsklinikum Mannheim

Mannheim, , 68167

Site Contact

Clinical.Trials@bms.com

855-907-3286

Johannes Wiesling Klinikum Minden, Minden, Germany

Status

Recruiting

Address

Johannes Wiesling Klinikum Minden

Minden, , 32429

Site Contact

Clinical.Trials@bms.com

855-907-3286

University Hospital of Alexandroupolis, Alexandroupolis, Greece

Status

Recruiting

Address

University Hospital of Alexandroupolis

Alexandroupolis, , 08100

Site Contact

Clinical.Trials@bms.com

855-907-3286

Evangelismos General Hospital of Athens, Athens, Greece

Status

Recruiting

Address

Evangelismos General Hospital of Athens

Athens, , 10676

Site Contact

Clinical.Trials@bms.com

855-907-3286

Laiko General Hospital of Athens, Athens, Greece

Status

Recruiting

Address

Laiko General Hospital of Athens

Athens, , 11 527

Site Contact

Clinical.Trials@bms.com

855-907-3286

Attikon university General Hospital, Athens, Greece

Status

Recruiting

Address

Attikon university General Hospital

Athens, , 12464

Site Contact

Clinical.Trials@bms.com

855-907-3286

University General Hospital of Patras, Rio Patras, Greece

Status

Recruiting

Address

University General Hospital of Patras

Rio Patras, , 26500

Site Contact

Clinical.Trials@bms.com

855-907-3286

Thessaloniki, Greece

Status

Recruiting

Address

Georgios Papanikolaou General Hospital of Thessaloniki

Thessaloniki, , 57010

Site Contact

Clinical.Trials@bms.com

855-907-3286

Queen Mary Hospital, Hong Kong, Hong Kong

Status

Recruiting

Address

Queen Mary Hospital

Hong Kong, ,

Site Contact

Clinical.Trials@bms.com

855-907-3286

Sha Tin, Hong Kong

Status

Recruiting

Address

Prince of Wales Hospital the Chinese University of Hong Kong

Sha Tin, ,

Site Contact

Clinical.Trials@bms.com

855-907-3286

Budapest, Hungary

Status

Not yet recruiting

Address

Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet

Budapest, , 1096

Site Contact

Clinical.Trials@bms.com

855-907-3286

Petz Aladár Egyetemi Oktató Kórház, Gyor, Hungary

Status

Not yet recruiting

Address

Petz Aladár Egyetemi Oktató Kórház

Gyor, , 9023

Site Contact

Clinical.Trials@bms.com

855-907-3286

Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary

Status

Not yet recruiting

Address

Somogy Megyei Kaposi Mor Oktato Korhaz

Kaposvar, , 7400

Site Contact

Clinical.Trials@bms.com

855-907-3286

Cork University Hospital, Cork, Ireland

Status

Not yet recruiting

Address

Cork University Hospital

Cork, , T12 DFK4

Site Contact

Clinical.Trials@bms.com

855-907-3286

Mater Misercordiae Hospital, Dublin 7, Ireland

Status

Recruiting

Address

Mater Misercordiae Hospital

Dublin 7, , 7

Site Contact

Clinical.Trials@bms.com

855-907-3286

St James Hospital, Dublin, Ireland

Status

Recruiting

Address

St James Hospital

Dublin, , Dublin 8

Site Contact

Clinical.Trials@bms.com

855-907-3286

Rambam Medical Center, Haifa, Israel

Status

Recruiting

Address

Rambam Medical Center

Haifa, , 31096

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hadassah Medical Organization, Jerusalem, Israel

Status

Recruiting

Address

Hadassah Medical Organization

Jerusalem, , 91120

Site Contact

Clinical.Trials@bms.com

855-907-3286

Meir Medical Center, Kfar-Saba, Israel

Status

Recruiting

Address

Meir Medical Center

Kfar-Saba, , 44281

Site Contact

Clinical.Trials@bms.com

855-907-3286

Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Status

Recruiting

Address

Tel-Aviv Sourasky Medical Center

Tel-Aviv, , 64239

Site Contact

Clinical.Trials@bms.com

855-907-3286

Shamir Medical Center - Assaf Harofeh, Zerifin, Israel

Status

Recruiting

Address

Shamir Medical Center - Assaf Harofeh

Zerifin, , 70300

Site Contact

Clinical.Trials@bms.com

855-907-3286

Ancona, Italy

Status

Recruiting

Address

Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi

Ancona, , 60126

Site Contact

Clinical.Trials@bms.com

855-907-3286

Bologna, Italy

Status

Recruiting

Address

Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi

Bologna, , 40138

Site Contact

Clinical.Trials@bms.com

855-907-3286

Catania, Italy

Status

Recruiting

Address

Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele - Ospedale Gaspare Rodolico

Catania, , 95123

Site Contact

Clinical.Trials@bms.com

855-907-3286

Firenze, Italy

Status

Recruiting

Address

Azienda Ospedaliera Universitaria Careggi

Firenze, , 50134

Site Contact

Clinical.Trials@bms.com

855-907-3286

Napoli Campania, Italy

Status

Recruiting

Address

Azienda Ospedaliera Universitaria Federico II

Napoli Campania, , 80131

Site Contact

Clinical.Trials@bms.com

855-907-3286

A.O.U. Maggiore della Carit, Novara, Italy

Status

Recruiting

Address

A.O.U. Maggiore della Carit

Novara, , 28100

Site Contact

Clinical.Trials@bms.com

855-907-3286

Azienda Ospedaliera di Padova, Padova, Italy

Status

Not yet recruiting

Address

Azienda Ospedaliera di Padova

Padova, , 35128

Site Contact

Clinical.Trials@bms.com

855-907-3286

Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

Status

Recruiting

Address

Azienda Ospedaliero Universitaria Pisana

Pisa, , 56124

Site Contact

Clinical.Trials@bms.com

855-907-3286

Reggio Di Calabria, Italy

Status

Recruiting

Address

Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli

Reggio Di Calabria, , 89124

Site Contact

Clinical.Trials@bms.com

855-907-3286

Azienda Ospedaliera Sant Andrea, Roma, Italy

Status

Recruiting

Address

Azienda Ospedaliera Sant Andrea

Roma, , 00189

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 251, Roma, Italy

Status

Recruiting

Address

Local Institution - 251

Roma, , 00189

Site Contact

Site 251

Clinical.Trials@bms.com

855-907-3286

Ospedale S Eugenio, Roma, Italy

Status

Recruiting

Address

Ospedale S Eugenio

Roma, , 144

Site Contact

Clinical.Trials@bms.com

855-907-3286

Azienda Ospedaliera S Maria di Terni, Terni, Italy

Status

Recruiting

Address

Azienda Ospedaliera S Maria di Terni

Terni, , 05100

Site Contact

Clinical.Trials@bms.com

855-907-3286

Varese, Italy

Status

Recruiting

Address

Universita degli Studi dell'Insubria - Ospedale di Circolo e Fondazione Macchi - Varese

Varese, , 21100

Site Contact

Clinical.Trials@bms.com

855-907-3286

Local Institution - 711, Osakasayama, Osaka, Japan

Status

Recruiting

Address

Local Institution - 711

Osakasayama, Osaka, 5898511

Site Contact

Site 711

Clinical.Trials@bms.com

855-907-3286

Aomori Prefectural Central Hospital, Aomori, Japan

Status

Recruiting

Address

Aomori Prefectural Central Hospital

Aomori, , 030-8553

Site Contact

Clinical.Trials@bms.com

855-907-3286

Juntendo University Hospital, Bunkyo-ku, Japan

Status

Recruiting

Address

Juntendo University Hospital

Bunkyo-ku, , 113-8431

Site Contact

Clinical.Trials@bms.com

855-907-3286

Bunkyo-ku, Japan

Status

Recruiting

Address

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Bunkyo-ku, , 113-8677

Site Contact

Clinical.Trials@bms.com

855-907-3286

University of Yamanashi Hospital, Chuo, Japan

Status

Recruiting

Address

University of Yamanashi Hospital

Chuo, , 409-3898

Site Contact

Clinical.Trials@bms.com

855-907-3286

Tokai University Hospital, Isehara City, Kanagawa, Japan

Status

Recruiting

Address

Tokai University Hospital

Isehara City, Kanagawa, , 259-1193

Site Contact

Clinical.Trials@bms.com

855-907-3286

Kameda General Hospital, Kamogawa, Japan

Status

Recruiting

Address

Kameda General Hospital

Kamogawa, , 296-8602

Site Contact

Clinical.Trials@bms.com

855-907-3286

Gunma University Hospital, Maebashi, Japan

Status

Recruiting

Address

Gunma University Hospital

Maebashi, , 371-8511

Site Contact

Clinical.Trials@bms.com

855-907-3286

University of Miyazaki Hospital, Miyazaki, Japan

Status

Recruiting

Address

University of Miyazaki Hospital

Miyazaki, , 889-1692

Site Contact

Clinical.Trials@bms.com

855-907-3286

Nagasaki, Japan

Status

Recruiting

Address

The Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, , 852-8511

Site Contact

Clinical.Trials@bms.com

855-907-3286

Kindai University Hospital, Osaka-Sayama, Japan

Status

Recruiting

Address

Kindai University Hospital

Osaka-Sayama, , 589-8511

Site Contact

Clinical.Trials@bms.com

855-907-3286

Osaka City University Hospital, Osaka, Japan

Status

Recruiting

Address

Osaka City University Hospital

Osaka, , 545-8586

Site Contact

Clinical.Trials@bms.com

855-907-3286

Sapporo Hokuyu Hospital, Sapporo, Japan

Status

Recruiting

Address

Sapporo Hokuyu Hospital

Sapporo, , 003-0006

Site Contact

Clinical.Trials@bms.com

855-907-3286

NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan

Status

Recruiting

Address

NTT Medical Center Tokyo

Shinagawa-ku, Tokyo, , 141-8625

Site Contact

Clinical.Trials@bms.com

855-907-3286

Shinjuku City, Japan

Status

Recruiting

Address

Tokyo Women's Medical University Hospital

Shinjuku City, , 162-8666

Site Contact

Clinical.Trials@bms.com

855-907-3286

Tokyo Medical University Hospital, Shinjyuku-ku, Japan

Status

Recruiting

Address

Tokyo Medical University Hospital

Shinjyuku-ku, , 160-0023

Site Contact

Clinical.Trials@bms.com

855-907-3286

Kyungpook National University Hospital, Daegu, Korea, Republic of

Status

Recruiting

Address

Kyungpook National University Hospital

Daegu, , 700-721

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hwasun-Gun, Korea, Republic of

Status

Recruiting

Address

Chonnam National University Hwasun Hospital

Hwasun-Gun, , 58128

Site Contact

Clinical.Trials@bms.com

855-907-3286

Seongnam-si, Korea, Republic of

Status

Recruiting

Address

Seoul National University Bundang Hospital

Seongnam-si, , 13620

Site Contact

Clinical.Trials@bms.com

855-907-3286

Samsung Medical Center, Seoul, Korea, Republic of

Status

Recruiting

Address

Samsung Medical Center

Seoul, , 135-710

Site Contact

Clinical.Trials@bms.com

855-907-3286

Seoul, Korea, Republic of

Status

Recruiting

Address

The Catholic University of Korea Seoul - Saint Mary's Hospital

Seoul, , 137-701

Site Contact

Clinical.Trials@bms.com

855-907-3286

Seoul National University Hospital, Seoul, Korea, Republic of

Status

Recruiting

Address

Seoul National University Hospital

Seoul, , 3080

Site Contact

Clinical.Trials@bms.com

855-907-3286

Asan Medical Center, Seoul, Korea, Republic of

Status

Recruiting

Address

Asan Medical Center

Seoul, , 5505

Site Contact

Clinical.Trials@bms.com

855-907-3286

Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

Status

Recruiting

Address

Uniwersyteckie Centrum Kliniczne

Gdansk, , 80-952

Site Contact

Clinical.Trials@bms.com

855-907-3286

Krakow, Poland

Status

Recruiting

Address

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Krakow, , 31-501

Site Contact

Clinical.Trials@bms.com

855-907-3286

Lodz, Poland

Status

Recruiting

Address

Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

Lodz, , 93-510

Site Contact

Clinical.Trials@bms.com

855-907-3286

ALVAMED, Poznan, Poland

Status

Recruiting

Address

ALVAMED

Poznan, , 61-696

Site Contact

Clinical.Trials@bms.com

855-907-3286

Walbrzych, Poland

Status

Recruiting

Address

Specjalistyczny Szpital im. dra Alfreda Sokolowskiego

Walbrzych, , 58-309

Site Contact

Clinical.Trials@bms.com

855-907-3286

Wroclaw, Poland

Status

Recruiting

Address

Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu

Wroclaw, , 50367

Site Contact

Clinical.Trials@bms.com

855-907-3286

Moscow, Russian Federation

Status

Terminated

Address

Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin

Moscow, , 125284

Site Contact

Clinical.Trials@bms.com

855-907-3286

St Petersburg, Russian Federation

Status

Terminated

Address

Federal Centre of Heart, Blood and Endocrinology of Rosmed technlologies V.A. Almazov

St Petersburg, , 197341

Site Contact

Clinical.Trials@bms.com

855-907-3286

St. Petersburg, Russian Federation

Status

Terminated

Address

First St Petersburg State Medical University na IP Pavlov

St. Petersburg, , 197022

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Clinic de Barcelona, Barcelona, Spain

Status

Recruiting

Address

Hospital Clinic de Barcelona

Barcelona, , 08036

Site Contact

Clinical.Trials@bms.com

855-907-3286

Barcelona, Spain

Status

Recruiting

Address

Hospital Universitari Germans Trias i Pujol ICO Badalona

Barcelona, , 08916

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Virgenes de las Nieves, Granada, Spain

Status

Recruiting

Address

Hospital Virgenes de las Nieves

Granada, , 18014

Site Contact

Clinical.Trials@bms.com

855-907-3286

Las Palmas de Gran Canaria, Spain

Status

Recruiting

Address

Hospital Universitario de Gran Canaria Dr. Negrin

Las Palmas de Gran Canaria, , 35012

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario Ramon y Cajal, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario Ramon y Cajal

Madrid, , 28034

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario 12 de Octubre, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario 12 de Octubre

Madrid, , 28041

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Son Espases, Palma de Mallorca, Spain

Status

Recruiting

Address

Hospital Son Espases

Palma de Mallorca, , 7120

Site Contact

Clinical.Trials@bms.com

855-907-3286

Salamanca, Spain

Status

Recruiting

Address

Universitario de Salamanca - Hospital Clinico

Salamanca, , 37007

Site Contact

Clinical.Trials@bms.com

855-907-3286

Santiago de Compostela, Spain

Status

Recruiting

Address

Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, , 15706

Site Contact

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario Virgen del Rocio, Seville, Spain

Status

Recruiting

Address

Hospital Universitario Virgen del Rocio

Seville, , 41013

Site Contact

Clinical.Trials@bms.com

855-907-3286

Valencia, Spain

Status

Recruiting

Address

Hospital Clinico Universitario de Valencia

Valencia, , 46010

Site Contact

Clinical.Trials@bms.com

855-907-3286

Heart of England NHS Foundation Trust, Birmingham, United Kingdom

Status

Recruiting

Address

Heart of England NHS Foundation Trust

Birmingham, , B9 5SS

Site Contact

Clinical.Trials@bms.com

855-907-3286

United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom

Status

Recruiting

Address

United Lincolnshire Hospitals NHS Trust

Boston, , PE21 9QS

Site Contact

Clinical.Trials@bms.com

855-907-3286

Guy's Cancer Centre, London, United Kingdom

Status

Not yet recruiting

Address

Guy's Cancer Centre

London, , SE1 9RT

Site Contact

Clinical.Trials@bms.com

855-907-3286

Nottingham City Hospital, Nottingham, United Kingdom

Status

Recruiting

Address

Nottingham City Hospital

Nottingham, , NG5 1PB

Site Contact

Clinical.Trials@bms.com

855-907-3286

Churchhill Hospital, Oxford, United Kingdom

Status

Recruiting

Address

Churchhill Hospital

Oxford, , OX3 7LI

Site Contact

Clinical.Trials@bms.com

855-907-3286

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

RSS MPN News

  • Contemporary Approach CALR Positive MPNs
  • 9 Tips to Reduce MPN Fatigue
  • Common Clinical Trial Acronyms and Abbreviations
  • Understanding the Phases of Clinical Trials
  • 4th Angel providing one-on-one support services for MPN Patients

MPN 2019 guidelines

MPN 2019 Guidelines, PV Reporter

Click on the image above for the New MPN Patient Guidelines! Very detailed, provided by NCCN.

Medical Dislaimer

Sign up for Our Newsletter!

Copyright · PV Reporter © 2021 · Site Design by David Wallace
error: